Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade

Journal of Hypertension
Jan MenneHermann Haller

Abstract

Microalbuminuria, the increase in urinary albumin excretion, has most often been linked with renal disease in diabetic patients. However, accumulating data demonstrate a link between albuminuria and cardiovascular disease in both diabetic and nondiabetic patients, even at very low levels of urinary albumin excretion once considered to be 'normal'. The reasons for the increase in cardiovascular risk may be linked to generalized vascular and endothelial dysfunction, mediated by the renin-angiotensin system and the angiotensin II type 1 receptor. Accordingly, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have demonstrated some success in treating microalbuminuria. With the prevalence of microalbuminuria at around 7% in the general population, and as high as 39% in diabetic patients, reducing and preventing microalbuminuria is becoming of increasing interest in helping to reduce cardiovascular risk. Subsequently, international guidelines have recommended screening for the presence of microalbuminuria in all patients with hypertension, diabetes or both.

References

Apr 1, 1989·Diabetologia·T DeckertA Kofoed-Enevoldsen
Feb 9, 1984·The New England Journal of Medicine·C E Mogensen
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Dec 14, 1996·Lancet·E A Nelson, L M Yu
Jan 1, 1997·Stroke; a Journal of Cerebral Circulation·T NakayamaH Tanaka
Jun 16, 1999·Archives of Neurology·N B BeamerM Wynn
Aug 14, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·K Borch-JohnsenJ S Jensen
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Mar 6, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Camille A JonesLawrence Y Agodoa
Oct 3, 2002·Circulation·Hans L HillegeUNKNOWN Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group
Feb 22, 2003·Journal of the American Society of Nephrology : JASN·Johannes F E MannSalim Yusuf
May 21, 2003·Hypertension·Giovanna LeonciniRoberto Pontremoli
Jun 26, 2003·Journal of Internal Medicine·C E Mogensen
Oct 23, 2003·JAMA : the Journal of the American Medical Association·UNKNOWN Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Resea
Apr 28, 2004·Diabetes Care·Mark E Molitch
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Oct 20, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robyn J TappRobert C Atkins
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Nov 26, 2004·Journal of the American Society of Nephrology : JASN·Bessie A YoungEdward J Boyko
Dec 25, 2004·Diabetes Care·UNKNOWN American Diabetes Association
Mar 2, 2005·Circulation·Thomas J WangRamachandran S Vasan

❮ Previous
Next ❯

Citations

Jan 9, 2013·Current Hypertension Reports·Lodi C W RoksnoerA H Jan Danser
Apr 21, 2011·Der Internist·J Menne, H Haller
Jan 11, 2012·Der Internist·C ChatzikyrkouJ Menne
Nov 14, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Jae-Hong RyooJu Young Jung
Jun 13, 2015·Current Hypertension Reports·Ulrich Kintscher
Sep 14, 2012·Clinical Science·Carolina Gutiérrez-RepisoAnna Bosch-Comas
Nov 17, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroko SugimoriHiroshi Inoue
Feb 25, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Vinicius J B MartinsAna L Sawaya
Jun 8, 2013·Journal of Hypertension·Frederik PerssonHans-Henrik Parving
Mar 19, 2020·Journal of Clinical Pathology·Glaucia VeigaFernando Fonseca
Nov 9, 2019·KI Reports·Florian G ScurtUNKNOWN ROADMAP Steering Committee
Nov 15, 2011·Journal of Hypertension·Cesar CerezoFranz H Messerli
Mar 16, 2012·Journal of Hypertension·Jan MenneUNKNOWN ROADMAP investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Journal of the American Society of Nephrology : JASN
Roland E SchmiederONTARGET Investigators
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Henri AfghahiMaria K Svensson
JAMA : the Journal of the American Medical Association
H C GersteinHOPE Study Investigators
© 2021 Meta ULC. All rights reserved